Full Press Release Details
Immutep Announces Publication of TACTI-002
and TACTI-003 Abstracts at ASCO 2022
SYDNEY, AUSTRALIA 27 May 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP)
( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce new interim data from
Part A of the Phase II TACTI-002 trial in 1st line NSCLC has been published today in an abstract at the American Society of Clinical Oncology s (ASCO)
2022 Annual Meeting.
Data from the trial will be presented in an Oral Presentation on 3 June 2022. Importantly, while the abstract contains data
from the first 75 patients with a data cut off of January 2022, the Oral Presentation will present data from all 114 patients with a more recent data cut off and will be the subject of a further announcement from the Company.
Immutep also announces the publication of an abstract for the design of the ongoing Phase IIb TACTI-003 trial that
will be presented as a Trial-in-Progress Poster Presentation at ASCO 2022.
The respective abstracts are available via the links below and www.immutep.com. Similarly, the presentations will be available at the times indicated
below on ASCO.org and subsequently made available on Immutep s website.
| Title: | A Phase II study (TACTI-002) in 1st line metastatic non-small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: updated results from a PD-L1 unselected population | |
| Abstract link: | https://www.immutep.com/files/content/investor/presentation/2022/ASCO 2022/ASCO 2022_TACTI-002 part A_Abstract_Final.pdf | |
| Oral presentation date: | Friday 3 June 2022 at 1:00pm, US Central Daylight Time (CDT) |
Level 33, Australia Square
264 George Street, Sydney NSW 2000
| Title: | TACTI-003: A randomized Phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous-cell carcinoma | |
| Abstract link: | https://www.immutep.com/files/content/investor/presentation/2022/ASCO 2022/ASCO 2022_TACTI-003_TIP_Abstract_Final.pdf | |
| Poster date: | Monday 6 June 2022 at 1:15pm US CDT |
a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging
its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
lead product candidate is eftilagimod alpha ( efti or IMP321 ), a soluble LAG-3 fusion protein (LAG-3Ig), which is a
first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep s large
pharmaceutical partners.
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Further information can be found on the Company s website www.immutep.com or by contacting:
Australian Investors/Media:
+61 (0)406 759 268; cstrong@citadelmagnus.com
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com
announcement was authorised for release by the Board of Immutep Limited.
Level 33, Australia Square
264 George Street, Sydney NSW 2000